CITATION REPORT List of articles citing

Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis

DOI: 10.1016/j.jpba.2012.06.003 Journal of Pharmaceutical and Biomedical Analysis, 2012, 70, 415-24.

Source: https://exaly.com/paper-pdf/53253168/citation-report.pdf

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
80	A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. <i>Rheumatology</i> , 2013 , 52, 1202-7	3.9	65
79	Mechanistic biomarkers for clinical decision making in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 267-76	8.1	72
78	ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. <i>Arthritis Research and Therapy</i> , 2013 , 15, R140	5.7	44
77	An evaluation of molecular and clinical remission in rheumatoid arthritis by assessing radiographic progression. <i>Rheumatology</i> , 2013 , 52, 839-46	3.9	54
76	Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. <i>Current Medical Research and Opinion</i> , 2013 , 29, 85-92	2.5	21
75	Impact of rheumatoid arthritis disease activity test on clinical practice. PLoS ONE, 2013, 8, e63215	3.7	15
74	Development of a multi-biomarker disease activity test for rheumatoid arthritis. <i>PLoS ONE</i> , 2013 , 8, e6	0635	117
73	A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. <i>Endocrine-Related Cancer</i> , 2014 , 21, 615-28	5.7	77
72	Understanding Evidence-Based Rheumatology. 2014 ,		
71	Labordiagnostik systemischer Autoimmunerkrankungen: Update 2013. <i>Laboratoriums Medizin</i> , 2014 , 38,		
70	Osteoarthritisa case for personalized health care?. Osteoarthritis and Cartilage, 2014, 22, 7-16	6.2	104
69	Rheumatoid arthritis: a case for personalized health care?. Arthritis Care and Research, 2014, 66, 1273-8	30 _{4.7}	19
68	A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. <i>Journal of Rheumatology</i> , 2014 , 41, 2114-9	4.1	33
67	Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples. <i>Journal of Immunological Methods</i> , 2014 , 408, 13-23	2.5	36
66	A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors. <i>Endocrine Connections</i> , 2014 , 3, 215-23	3.5	37
65	Laboratory diagnostics of systemic autoimmune diseases IJpdate 2013. <i>Laboratoriums Medizin</i> , 2015 , 38,		
64	A multi-biomarker disease activity score for monitoring rheumatoid arthritis. <i>Current Biomarker Findings</i> , 2015 , 69		2

(2016-2015)

63	The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. <i>American Journal of Gastroenterology</i> , 2015 , 110, 1223-32	0.7	62	
62	Early biomarkers of joint damage in rheumatoid and psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 141	5.7	49	
61	Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management. <i>Current Rheumatology Reports</i> , 2015 , 17, 35	4.9	10	
60	A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study. <i>Modern Rheumatology</i> , 2015 , 25, 344-9	3.3	14	
59	Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1102-9	2.4	76	
58	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , 2015 , 161, 2-10	9	37	
57	Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity?. <i>BMJ, The</i> , 2015 , 351, h5079	5.9	41	
56	A direct heating model to overcome the edge effect in microplates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 102, 199-202	3.5	7	
55	A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-treatment of psoriatic arthritis. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 645-62	3.1	17	
54	Editorial: The Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis: Is It a Valid Measure of Disease Activity?. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2061-6	9.5	6	
53	Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial. <i>RMD Open</i> , 2016 , 2, e000197	5.9	19	
52	Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks?. <i>Arthritis Research and Therapy</i> , 2016 , 18, 163	5.7	32	
51	A multiplex urinary immunoassay for bladder cancer detection: analysis of a Japanese cohort. Journal of Translational Medicine, 2016 , 14, 287	8.5	20	
50	Assessment of disease activity in rheumatoid arthritis by multi-biomarker disease activity (MBDA) score. <i>Japanese Journal of Clinical Immunology</i> , 2016 , 39, 37-41		6	
49	Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data. <i>RMD Open</i> , 2016 , 2, e000245	5.9	12	
48	Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery. <i>Proteomics - Clinical Applications</i> , 2016 , 10, 691-8	3.1	18	
47	Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. <i>Clinica Chimica Acta</i> , 2016 , 459, 177-186	6.2	48	
46	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology, 2016, 26, 850-856	3.3	13	

45	Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2016 , 36, 295-300	3.6	15
44	Reanalysis of the Multi-Biomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologic-Naive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. <i>Arthritis and</i>	9.5	8
43	Translational Research: Preclinical to Healthy Volunteer to Patient. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017 , 341-372	0.5	1
42	A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes. <i>Rheumatology</i> , 2017 , 56, 973-980	3.9	14
41	The acute-phase mediator serum amyloid A is associated with symptoms of depression and fatigue. <i>Acta Psychiatrica Scandinavica</i> , 2017 , 135, 409-418	6.5	10
40	A Multi-Biomarker Disease Activity Score and the Choice of Second-Line Therapy in Early Rheumatoid Arthritis After Methotrexate Failure. <i>Arthritis and Rheumatology</i> , 2017 , 69, 953-963	9.5	22
39	Quantitative analysis of four protein biomarkers: An automated microfluidic cartridge-based method and its comparison to colorimetric ELISA. <i>Journal of Immunological Methods</i> , 2017 , 451, 1-10	2.5	15
38	Parallelism experiments to evaluate matrix effects, selectivity and sensitivity in ligand-binding assay method development: pros and cons. <i>Bioanalysis</i> , 2017 , 9, 1107-1122	2.1	22
37	Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 353-358	1.9	13
36	Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part two. <i>Pediatric Rheumatology</i> , 2017 , 15,	3.5	3
35	Biologic Markers in Clinical Trials and Clinical Care. 2017 , 509-519		
34	Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs. <i>Clinical Reviews in Allergy and Immunology</i> , 2018 , 55, 271-294	12.3	34
33	Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018 , 8, 585	5.3	11
32	Proteomics in Chronic Arthritis-Will We Finally Have Useful Biomarkers?. <i>Current Rheumatology Reports</i> , 2018 , 20, 53	4.9	2
31	Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment. <i>PLoS ONE</i> , 2018 , 13, e0192425	3.7	11
30	Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 9-16	1.9	14
29	Serum Biomarkers for Prediction of Response to Methotrexate Monotherapy in Early Rheumatoid Arthritis: Results from the SWEFOT Trial. <i>Journal of Rheumatology</i> , 2019 , 46, 555-563	4.1	8
28	ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation. <i>Arthritis Research and Therapy</i> , 2019 , 21, 121	5.7	14

(2021-2019)

27	Haemolysis and lipemia interfere with resistin and myeloperoxidase BioVendor ELISA assays. <i>Biochemia Medica</i> , 2019 , 29, 020703	2.5	4
26	Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores. <i>Clinical Rheumatology</i> , 2019 , 38, 437-445	3.9	7
25	Correlation of the Multi-Biomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Meta-Analysis. <i>Arthritis Care and Research</i> , 2019 , 71, 1459-7	1472	19
24	Measures of Rheumatoid Arthritis Disease Activity. Arthritis Care and Research, 2020, 72 Suppl 10, 4-26	4.7	O
23	Emerging Technologies and Platforms for the Immunodetection of Multiple Biochemical Markers in Osteoarthritis Research and Therapy. <i>Frontiers in Medicine</i> , 2020 , 7, 572977	4.9	16
22	An interdigitated aptasensor to detect interleukin-6 for diagnosing rheumatoid arthritis in serum. <i>Biotechnology and Applied Biochemistry</i> , 2020 ,	2.8	1
21	The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial. <i>Arthritis Research and Therapy</i> , 2020 , 22, 205	5.7	2
20	Contribution of Multiplex Immunoassays to Rheumatoid Arthritis Management: From Biomarker Discovery to Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2020 , 10,	3.6	8
19	What further data are needed to value the Multi-Biomarker Disease Activity score for measuring rheumatoid arthritis disease activity: comment on the article by Johnson et al. <i>Arthritis Care and Research</i> , 2020 , 72, 1339-1340	4.7	2
18	Correlation of serum protein biomarkers with disease activity in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 335-341	5.1	5
17	Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021 , 58, 17-28	9.4	1
16	Identification of a Novel Serum Proteomic Signature for Primary Sjgrend Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 631539	8.4	3
15	Serum chitinase-3-like 1 protein is a useful biomarker to assess disease activity in ANCA-associated vasculitis: an observational study. <i>Arthritis Research and Therapy</i> , 2021 , 23, 77	5.7	0
14	Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission. <i>Scientific Reports</i> , 2021 , 11, 6865	4.9	4
13	Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?. <i>Expert Review of Proteomics</i> , 2021 , 18, 159-175	4.2	1
12	Performance of a commercially available multiplex platform in the assessment of circulating cytokines and chemokines in patients with rheumatoid arthritis and osteoarthritis. <i>Journal of Immunological Methods</i> , 2021 , 495, 113048	2.5	1
11	Increased sTREM-1 levels identify cirrhotic patients with bacterial infection and predict their 90-day mortality. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101579	2.4	3
10	Biomarker and data science as integral part of precision medicine. 2021 , 65-96		

9	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. <i>Health Technology Assessment</i> , 2018 , 22, 1-294	4.4	6
8	Biomarkers, Genetic Association, and Genomic Studies. 2014 , 79-126		
7	Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution <i>Arthritis Research and Therapy</i> , 2022 , 24, 4	5.7	1
6	Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021 , 59, 693-699	0.9	
5	Table_1.DOCX. 2018 ,		
4	Analytical validation of a multivariate proteomic serum-based assay for disease activity assessments in multiple sclerosis.		O
3	IL-31 and IL-33 in rheumatoid arthritis patients. 2022 , 60, 554-559		O
2	Recent advancement in sensitive detection of carcinoembryonic antigen using nanomaterials based immunosensors. 2023 , 36, 102596		O
1	Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. 2200018		0